HCW Biologics in Strong Momentum After FDA Clearance to Proceed with Phase 1b Clinical Trial for Potential Pancreatic Cancer Treatment
HCW Biologics Inc. (NASDAQ: HCWB) shares jumped more than 65% on Thursday after the biopharmaceutical Company announced that it has received clearance from the FDA to proceed to evaluate its lead drug candidate, HCW9218, in a first-in-human Phase 1b clinical...